AI assistant
USCOM LIMITED — Capital/Financing Update 2009
Sep 24, 2009
65979_rns_2009-09-24_98c0811c-56cb-4976-a7b0-a67a39843cf7.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Uscom Limited ABN 35091028090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
M A R K E T A N N O U N C E M E N T
Spacelabs Healthcare to Launch Uscom in the UK
Friday 25 September 2009: Uscom (ASX code: UCM) today informed shareholders that Spacelabs Healthcare intend to launch Uscom in the United Kingdom market on 1 October 2009.
As part of their global distribution agreement with Uscom Ltd, Spacelabs Healthcare are planning the product launch of the USCOM 1A into the UK. This is an important step in the global USCOM rollout as the UK is a sophisticated bio-device market already sensitized to the USCOM technology. Uscom has established some early milestones in the UK with Key Opinion Leaders using the product and publishing peer reviewed papers on the device, and dedicated market support already in country.
Spacelabs are building their capability in the UK to enhance these early positive steps that Uscom has already made. To support this UK push Uscom is planning some specific joint marketing activities in the UK in the coming months to further activate the acceptance and take-up of the USCOM product.
Uscom would also like to remind shareholders that the Share Purchase Plan (SPP) closes on Monday 28 September 2009. The board is pleased with the uptake to date and do not intend to extend the offer.
About Uscom
Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration. USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, India and Australia by Spacelabs Healthcare, while in China and SE Asia USCOM is distributed by Pacific Medical Systems and in New Zealand it is distributed by MedXus.
Uscom Contacts
Paul Butler Chief Executive Officer [email protected]
Rob Phillips Executive Chairman [email protected]